Dr. Jonathan D. Condit, DO
Family Medicine (Family Medicine Physician)
3631 N Morrison Rd
Muncie, IN 47304
Who else practices at this address →
Delaware County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 270
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
IN license 02000876
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
Medical groups
- American Health Network of Indiana LLC (208 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 270
- Services billed
- 2,251
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 756 | 226 |
| Insertion of needle into vein for collection of blood sample | 420 | 209 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 178 | 178 |
| Administration of influenza virus vaccine | 115 | 115 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 89 | 89 |
| Detection test by immunoassay with direct visual observation for influenza virus | 50 | 23 |
| Established patient office or other outpatient visit, 20-29 minutes | 44 | 32 |
| Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | 26 | 26 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 25 | 23 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 23 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Muncie, IN | 871 |
| Levothyroxine Sodium Other prescribers in Muncie, IN | 464 |
| Amlodipine Besylate Other prescribers in Muncie, IN | 455 |
| Rosuvastatin Calcium Other prescribers in Muncie, IN | 440 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Muncie, IN | 397 |
| Fluticasone Propionate Other prescribers in Muncie, IN | 389 |
| Ramipril Other prescribers in Muncie, IN | 362 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Muncie, IN | 345 |
| Tamsulosin Hcl Other prescribers in Muncie, IN | 322 |
| Gabapentin Other prescribers in Muncie, IN | 296 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 18 payments worth $716 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $386 |
|---|---|
| Novo Nordisk Inc | $162 |
| Exact Sciences Corporation | $47.90 |
| Pfizer Inc. | $44.78 |
| GlaxoSmithKline, LLC. | $22.33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 |
| Merck Sharp & Dohme LLC | $17.57 |
| Medtronic, Inc. | $16.22 |
| Food and Beverage | $697 |
|---|---|
| Education | $18.85 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 19, 2025 | Education JARDIANCE · DIABETES · in-kind | $18.85 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 5 companies. The companies reported $244,689 in research payments for these studies, mostly to the institutions running them.
- A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company · Completed · NCT05536804 - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421 - A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Eli Lilly and Company · Completed · NCT05971940 - A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascula…
Novartis Pharmaceuticals Corporation - Study name not reported
Novo Nordisk As - A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
Eli Lilly and Company · Recruiting · NCT06566170 - A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT02942914 - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim International GmbH - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.